News
THTX
1.470
+5.00%
0.070
Theratechnologies Gains FDA Approval for New Tesamorelin Formulation
TipRanks · 1d ago
Weekly Report: what happened at THTX last week (0324-0328)?
Weekly Report · 2d ago
Theratechnologies rises after FDA label expansion for best seller Egrifta
Seeking Alpha · 03/26 15:10
U.S.-LISTED SHARES OF THERATECHNOLOGIES UP 23% AFTER FDA APPROVES NEW TREATMENT FOR ABDOMINAL FAT IN HIV PATIENTS
Reuters · 03/26 13:35
BUZZ-U.S. STOCKS ON THE MOVE-Chewy, V2X, Cintas
Reuters · 03/26 13:26
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Theratechnologies (THTX), KalVista Pharmaceuticals (KALV) and Mereo Biopharma Group Plc (MREO)
TipRanks · 03/26 13:20
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
Benzinga · 03/26 10:18
BUZZ-Theratechnologies gets FDA nod for new treatment of abdominal fat in HIV patients, shares soar
Reuters · 03/26 09:46
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 03/26 09:00
Futures Flat Awaiting Clarity on Tariffs
Barchart · 03/26 06:35
THTX : FDA Oks EGRIFTA WR To Treat Excess Visceral Abdominal Fat In Adults With HIV & Lipodystrophy
NASDAQ · 03/26 02:44
Theratechnologies Gains FDA Nod for Enhanced HIV Treatment
TipRanks · 03/26 00:25
Stocks to Watch: GameStop, SurgePays, Theratechnologies
Dow Jones · 03/25 23:40
Theratechnologies Shares Rise on FDA Approval for HIV-Induced Stomach Fat Treatment
Dow Jones · 03/25 22:16
Theratechnologies announces FDA approval of sBLA for F8 formulation of tesamorel
TipRanks · 03/25 21:50
Theratechnologies Says FDA Approved Supplemental Biologics License Application For F8 Formulation Of Tesamorelin For Injection
Benzinga · 03/25 21:47
THERATECHNOLOGIES INC: EGRIFTA WR WILL BE MANUFACTURED AT A NEW, U.S.-BASED CONTRACT DRUG MANUFACTURING ORGANIZATION
Reuters · 03/25 21:45
THERATECHNOLOGIES RECEIVES FDA APPROVAL FOR EGRIFTA WR™ (TESAMORELIN F8) TO TREAT EXCESS VISCERAL ABDOMINAL FAT IN ADULTS WITH HIV AND LIPODYSTROPHY
Reuters · 03/25 21:45
Weekly Report: what happened at THTX last week (0317-0321)?
Weekly Report · 03/24 12:14
Weekly Report: what happened at THTX last week (0310-0314)?
Weekly Report · 03/17 12:29
More
Webull provides a variety of real-time THTX stock news. You can receive the latest news about Theratechnologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About THTX
More
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.